Enzene inaugurates its cutting-edge R&D facility in Pune, Health News, ET HealthWorld

[ad_1]

Pune: Enzene Biosciences Ltd announced the inauguration of its cutting-edge research and development (R&D) facility in Pune. The new R&D facility, spanning over 75,000 square feet, is equipped with an open lab set-up that promotes cross-departmental collaboration, efficient communication, and knowledge sharing.

The facility showcases the company’s dedication to advancing scientific research and development, offering fully integrated services from cell line development to fill & finish across a wide range of modalities. By breaking down traditional barriers, Enzene aims to facilitate seamless cross-functional interactions, which are proven to spark creativity and drive innovation.

Within the new R&D facility, the company has established specialised departments, including cell line engineering (CLE), drug product development (DPD), purification process development (PPD), advanced analytical technology (AAT), and bioanalytical assay.

“We are thrilled to inaugurate this state-of-the-art facility which embodies our unwavering commitment to pioneering research and development,” said Dr Himanshu Gadgil, CEO, Enzene. “The open lab setup is a testament to our belief in fostering a culture of collaboration, where ideas can flow freely, leading to transformative discoveries. Moreover, this facility will significantly enhance our capabilities to serve our valued CDMO partners with greater efficiency and excellence.”

The new R&D facility not only facilitates advanced research and development activities but also strengthens their specialised capabilities. “The inauguration of the R&D centre not only marks a momentous occasion for Enzene Biosciences but also highlights the company’s dedication to elevating the biopharmaceutical landscape and delivering on its promise of driving positive impact in global healthcare,” said Sandeep Singh, MD, Alkem Labs. “These strategic developments will invigorate our plans to become a global CDMO player.”

The company aims to further strengthen its partnership with CDMO clients by providing them with access to cutting-edge technologies and an extended portfolio of services. Enzene aspires to become a modality-agnostic biologics solution provider. The company is strategically expanding into innovative areas such as antibody-drug conjugates (ADC) and cell and gene therapies (CGT). By venturing into these domains, the company seeks to leverage its scientific expertise and state-of-the-art infrastructure to develop disruptive treatments for various challenging diseases.

  • Published On Sep 5, 2023 at 12:33 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *